NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555 · see citing works

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · see citing works

Inflammatory responses and inflammation-associated diseases in organs

Chen, L., Deng, H., Cui, H., Fang, J. S., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2017) · Oncotarget · doi:10.18632/oncotarget.23208 · Cited by 5,280 · see citing works

Drug repurposing: progress, challenges and recommendations

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718 · see citing works

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · see citing works

mTOR: from growth signal integration to cancer, diabetes and ageing

Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · see citing works

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383 · see citing works

Mechanisms of Insulin Action and Insulin Resistance

Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · see citing works

Mechanisms for Insulin Resistance: Common Threads and Missing Links

Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294 · see citing works

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100 · see citing works

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084 · see citing works

ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery

Jung, C. H., Jun, C. B., Ro, S.-H., Kim, Y.-M., Otto, N. M., Cao, J., Kundu, M., & Kim, D.-H. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1249 · Cited by 2,025 · see citing works

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020 · see citing works

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677 · see citing works

The PI3K/AKT Pathway in Obesity and Type 2 Diabetes

Huang, X., Liu, G., Guo, J., & Su, Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27173 · Cited by 1,673 · see citing works

ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy

Ganley, I. G., Lam, D., Wang, J., Ding, X., Chen, S., & Jiang, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900573200 · Cited by 1,559 · see citing works

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413 · see citing works

Rapamycin: one drug, many effects

Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287 · see citing works

mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway

Peterson, T. R., Sengupta, S., Harris, T. E., Carmack, A. E., Kang, S. A. W., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,233 · see citing works

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199 · see citing works

Liver immunology and its role in inflammation and homeostasis

Robinson, M. W., Harmon, C., & O’Farrelly, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.3 · Cited by 1,151 · see citing works

Inflammasome activation and regulation: toward a better understanding of complex mechanisms

Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Discovery · doi:10.1038/s41421-020-0167-x · Cited by 1,042 · see citing works

Regulation and function of mTOR signalling in T cell fate decisions

Chi, H. (2012) · Nature Reviews Immunology · doi:10.1038/nri3198 · Cited by 1,035 · see citing works

TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop

Settembre, C., De Cegli, R., Mansueto, G., Saha, P. K., Vetrini, F., Visvikis, O., Huynh, T., Carissimo, A., Palmer, D., Jürgen Klisch, T., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2718 · Cited by 1,022 · see citing works

Signaling and Function of Interleukin-2 in T Lymphocytes

Ross, S. H., & Cantrell, D. A. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053352 · Cited by 969 · see citing works

Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss

Pouwels, S., Sakran, N., Graham, Y. N. H., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K. K., & Ramnarain, D. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00980-1 · Cited by 912 · see citing works

Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification

Reghupaty, S. C., Fisher, P. B., & Sarkar, D. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.001 · Cited by 865 · see citing works

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850 · see citing works

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844 · see citing works

Regulation of Immune Responses by mTOR

Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · see citing works

Current status and future trends of the global burden of MASLD

Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781 · see citing works

Management of Hepatocellular Carcinoma

Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2022.7989 · Cited by 779 · see citing works

Targeting mTOR for cancer therapy

Hua, H., Kong, Q.-B., Zhang, H., Wang, J., Luo, T., & Jiang, Y.-F. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 772 · see citing works

Regulation and metabolic functions of mTORC1 and mTORC2.

Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 723 · see citing works

Metformin in non-alcoholic steatohepatitis.

Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682 · see citing works

Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes

Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678 · see citing works

Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways

Yecies, J. L., Zhang, H., Menon, S., Liu, S., Yecies, D. W., Lipovsky, A. I., Görgün, C. Z., Kwiatkowski, D. J., Hotamışlıgil, G. S., Lee, C., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.002 · Cited by 655 · see citing works

Insulin regulation of gluconeogenesis

Hatting, M., Tavares, C. D. J., Sharabi, K., Rines, A. K., & Puigserver, P. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13435 · Cited by 589 · see citing works

Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States

Younossi, Z. M., Stepanova, M., Ong, J. P., Trimble, G., Alqahtani, S. A., Younossi, I. M., Ahmed, A., Racila, A., & Henry, L. L. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.064 · Cited by 587 · see citing works

A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer

Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583 · see citing works

Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c

Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 551 · see citing works

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer

Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A., Kumar, D. P., Daita, K., Min, H.-K., Mirshahi, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.005 · Cited by 538 · see citing works

Obesity: A Chronic Low-Grade Inflammation and Its Markers

Khanna, D., Khanna, S., Khanna, P., Kahar, P., & Patel, B. M. (2022) · Cureus · doi:10.7759/cureus.22711 · Cited by 531 · see citing works

Adipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration

Polak, P., Cybulski, N., Feige, J. N., Auwerx, J., Rüegg, M. A., & Hall, M. N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.003 · Cited by 480 · see citing works

Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling

He, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S. E., Jepsen, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.031 · Cited by 469 · see citing works

Histopathology of nonalcoholic fatty liver disease

Brunt, E. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i42.5286 · Cited by 448 · see citing works

mTORC1 and mTORC2 in cancer and the tumor microenvironment

Kim, L. C., Cook, R. S., & Chen, J. (2016) · Oncogene · doi:10.1038/onc.2016.363 · Cited by 443 · see citing works

Mitochondrial alterations in fatty liver diseases

Fromenty, B., & Roden, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.020 · Cited by 430 · see citing works

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview

Parthasarathy, G., Revelo, X. S., & Malhi, H. (2020) · Hepatology Communications · doi:10.1002/hep4.1479 · Cited by 420 · see citing works

mTORC2 Promotes Tumorigenesis via Lipid Synthesis

Guri, Y., Colombi, M., Dazert, E., Hindupur, S. K., Roszik, J., Moes, S., Jenoe, P., Heim, M. H., Riezman, I., Riezman, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.011 · Cited by 410 · see citing works

Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial

Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology · doi:10.1002/hep.31843 · Cited by 379 · see citing works

Targeting the biology of aging with mTOR inhibitors

Mannick, J. B., & Lamming, D. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00416-y · Cited by 372 · see citing works

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 370 · see citing works

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354 · see citing works

Pathogenesis and Prevention of Hepatic Steatosis.

Nassir, F., Rector, R. S., Hammoud, G. M., & Ibdah, J. A. (2015) · PubMed Central · Cited by 321 · see citing works

Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis

Guo, J., & Friedman, S. L. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-21 · Cited by 315 · see citing works

Role of nonresolving inflammation in hepatocellular carcinoma development and progression

Yu, L., Yan, L., & Wang, H. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 302 · see citing works

The role of mammalian target of rapamycin (mTOR) in insulin signaling

Yoon, M.-S. (2017) · Nutrients · doi:10.3390/nu9111176 · Cited by 300 · see citing works

The multifaceted role of mTORC1 in the control of lipid metabolism

Ricoult, S. J. H., & Manning, B. D. (2013) · EMBO Reports · doi:10.1038/embor.2013.5 · Cited by 287 · see citing works

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma

Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 287 · see citing works

Connecting mTORC1 signaling to SREBP-1 activation

Bakan, I., & Laplante, M. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dd03 · Cited by 283 · see citing works

NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.

Foerster, F., Gairing, S., Müller, L., & Galle, P. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.007 · Cited by 265 · see citing works

Fat Cell–Specific Ablation of Rictor in Mice Impairs Insulin-Regulated Fat Cell and Whole-Body Glucose and Lipid Metabolism

Kumar, A. T., Lawrence, J. C., Jung, D. Y., Ko, H. J., Keller, S. R., Kim, J. K., Magnuson, M. A., & Harris, T. E. (2010) · Diabetes · doi:10.2337/db09-1061 · Cited by 250 · see citing works

The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis

Herman, M. A., & Samuel, V. T. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.005 · Cited by 249 · see citing works

MAFLD: a multisystem disease

Pipitone, R. M., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Tulone, A., Pennisi, G., Grimaudo, S., & Petta, S. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221145549 · Cited by 239 · see citing works

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Dharmalingam, M., & Yamasandhi, P. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_585_17 · Cited by 239 · see citing works

Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation

Tacer, K. F., & Rozman, D. (2011) · Journal of Lipids · doi:10.1155/2011/783976 · Cited by 232 · see citing works

NAFLD‐related hepatocellular carcinoma: The growing challenge

Shah, P. A., Patil, R., & Harrison, S. A. (2022) · Hepatology · doi:10.1002/hep.32542 · Cited by 232 · see citing works

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments

Peng, C. Y., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 230 · see citing works

Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease

Ma, Y., Lee, G., Heo, S.-Y., & Roh, Y. (2021) · Antioxidants · doi:10.3390/antiox11010091 · Cited by 227 · see citing works

Targeting mTOR and Metabolism in Cancer: Lessons and Innovations

Magaway, C., Kim, E., & Jacinto, E. (2019) · Cells · doi:10.3390/cells8121584 · Cited by 225 · see citing works

Energy and Fructose From Beverages Sweetened With Sugar or High-Fructose Corn Syrup Pose a Health Risk for Some People

Bray, G. A. (2013) · Advances in Nutrition · doi:10.3945/an.112.002816 · Cited by 222 · see citing works

Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma

Younossi, Z. M., & Henry, L. L. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100305 · Cited by 218 · see citing works

NLRC3 is an inhibitory sensor of PI3K–mTOR pathways in cancer

Karki, R., Man, S. M., Malireddi, R. K. S., Kesavardhana, S., Zhu, Q., Burton, A. R., Sharma, B. R., Qi, X., Pelletier, S. W., Vogel, P., et al. (2016) · Nature · doi:10.1038/nature20597 · Cited by 215 · see citing works

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH

Horn, C. L., Morales, A. L., Savard, C. E., Farrell, G. C., & Ioannou, G. N. (2021) · Hepatology Communications · doi:10.1002/hep4.1801 · Cited by 215 · see citing works

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

Ali, E. S., Mitra, K., Akter, S., Ramproshad, S., Mondal, B., Khan, I. N., Islam, M. T., Sharifi‐Rad, J., Călina, D. C., & Cho, W. C. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02706-8 · Cited by 213 · see citing works

mTOR-Dependent Cell Survival MechanismsPreprint

Hung, C., García-Haro, L., Sparks, C. A., & Guertin, D. A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008771 · Cited by 206 · see citing works

How big a problem is non-alcoholic fatty liver disease?

Anstee, Q. M., McPherson, S., & Day, C. (2011) · BMJ · doi:10.1136/bmj.d3897 · Cited by 200 · see citing works

A Systematic Review of Animal Models of NAFLD Finds High‐Fat, High‐Fructose Diets Most Closely Resemble Human NAFLD

Im, Y. R., Hunter, H., de Gracia Hahn, D., Duret, A., Cheah, Q., Dong, J., Fairey, M., Hjalmarsson, C., Li, A., Lim, H. K., et al. (2021) · Hepatology · doi:10.1002/hep.31897 · Cited by 195 · see citing works

Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition

Umemura, A., Park, E. J., Taniguchi, K., Lee, J. H., Shalapour, S., Valasek, M. A., Aghajan, M., Nakagawa, H., Seki, E., Hall, M. N., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.001 · Cited by 183 · see citing works

Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice

Menon, S., Yecies, J. L., Zhang, H., Howell, J. J., Nicholatos, J. W., Harputlugil, E., Bronson, R. T., Kwiatkowski, D. J., & Manning, B. D. (2012) · Science Signaling · doi:10.1126/scisignal.2002739 · Cited by 183 · see citing works

PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

Fiévet, C., Fruchart, J., & Staels, B. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.009 · Cited by 182 · see citing works

Muscle and adipose tissue insulin resistance: malady without mechanism?

Fazakerley, D. J., Krycer, J. R., Kearney, A. L., HOCKING, S. L., & James, D. E. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r087510 · Cited by 181 · see citing works

Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease

Ramanathan, R., Ali, A. H., & Ibdah, J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137280 · Cited by 179 · see citing works

Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins

Schreiber, K. H., Ortiz, D., Academia, E. C., Anies, A. C., Liao, C., & Kennedy, B. K. (2015) · Aging Cell · doi:10.1111/acel.12313 · Cited by 177 · see citing works

Natural History of NAFLD: Remarkably Benign in the Absence of Cirrhosis

Day, C. P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.041 · Cited by 176 · see citing works

mTORC1 signaling in hepatic lipid metabolism

Han, J., & Wang, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0409-3 · Cited by 168 · see citing works

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

Ducreux, M. P., Abou‐Alfa, G. K., Bekaii‐Saab, T., Berlin, J. D., Cervantes, A. M. R., de Baère, T., Eng, C., Galle, P. R., Gill, S., Gruenberger, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101567 · Cited by 167 · see citing works

Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis

Hansen, H. H., Ægidius, H. M., Oró, D., Evers, S. S., Heebøll, S., Eriksen, P. L., Thomsen, K. L., Bengtsson, A., Veidal, S. S., Feigh, M., et al. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01356-2 · Cited by 157 · see citing works

Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK–mTOR–SREBP signaling pathway

Quan, H. Y., Kim, D. Y., Kim, S. J., Jo, H. K., Kim, G. W., & Chung, S. H. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.007 · Cited by 155 · see citing works

Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1

Gosis, B. S., Wada, S., Thorsheim, C. L., Li, K., Jung, S., Rhoades, J. H., Yang, Y., Brandimarto, J., Li, L., Uehara, K., et al. (2022) · Science · doi:10.1126/science.abf8271 · Cited by 155 · see citing works

Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial

Eckard, C. S., Cole, R. E., Lockwood, J., Torres, D. M., Williams, C. D., Shaw, J. C., & Harrison, S. A. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13484078 · Cited by 155 · see citing works

The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes

Brown, N. F., Stefanović-Račić, M., SIPULA, I. J., & Perdomo, G. (2007) · Metabolism · doi:10.1016/j.metabol.2007.06.016 · Cited by 152 · see citing works

Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality

Simon, T. G., Roelstraete, B., Hartjes, K. T., Shah, U. S., Khalili, H., Arnell, H., & Ludvigsson, J. F. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.034 · Cited by 151 · see citing works

Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity

Lonardo, A., Mantovani, A., Lugari, S., & Targher, G. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.03.001 · Cited by 150 · see citing works

Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis

De Munck, T. J. I., Xu, P., Verwijs, H. J. A., Masclee, A. A. M., Jonkers, D., Verbeek, J., & Koek, G. H. (2020) · Liver International · doi:10.1111/liv.14696 · Cited by 145 · see citing works

Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention

Lange, N. F., Radu, P., & Dufour, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.025 · Cited by 137 · see citing works

Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma

Ferrín, G., Misas, M. G., Amado, V., Rodríguez‐Perálvarez, M., & de la Mata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041266 · Cited by 137 · see citing works

Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study

Zhang, X., Wu, M., Liu, Z., Yuan, H., Wu, X., Shi, T., Chen, X., & Zhang, T. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042843 · Cited by 131 · see citing works

Evolving Role for Pharmacotherapy in NAFLD/NASH

Attia, S. L., Softic, S., & Mouzaki, M. (2020) · Clinical and Translational Science · doi:10.1111/cts.12839 · Cited by 130 · see citing works

Major involvement of mTOR in the PPARγ-induced stimulation of adipose tissue lipid uptake and fat accretion

Blanchard, P.-G., Festuccia, W. T., Houde, V. P., St‐Pierre, P., Brûlé, S., Turcotte, V., Côté, M., Bellmann, K., Marette, A., & Deshaies, Y. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m021485 · Cited by 129 · see citing works

Inflammatory Reaction in Neurological Diseases

Wang, H., Lu, C., Cheng, K., & Chiang, J. (2014) · BioMed Research International · doi:10.1155/2014/408514 · Cited by 122 · see citing works

Recent Epidemiology of Nonalcoholic Fatty Liver Disease

Murag, S., Ahmed, A., & Kim, D. (2020) · Gut and Liver · doi:10.5009/gnl20127 · Cited by 121 · see citing works

Toward More Accurate Nomenclature for Fatty Liver Diseases

Eslam, M., Sanyal, A. J., & George, J. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.064 · Cited by 115 · see citing works

Role of vitamin E in nonalcoholic fatty liver disease

Nagashimada, M., & Ota, T. (2018) · IUBMB Life · doi:10.1002/iub.1991 · Cited by 113 · see citing works

Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents

Tokuhara, D. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.700058 · Cited by 104 · see citing works

Hepatocellular carcinoma in a mouse model fed a choline‐deficient, L‐amino acid‐defined, high‐fat diet

Ikawa‐Yoshida, A., Matsuo, S., Kato, A., Ohmori, Y., Higashida, A., Kaneko, E., & Matsumoto, M. (2017) · International Journal of Experimental Pathology · doi:10.1111/iep.12240 · Cited by 98 · see citing works

The integral role of mTOR in lipid metabolism

Soliman, G. A. (2011) · Cell Cycle · doi:10.4161/cc.10.6.14930 · Cited by 96 · see citing works

Role of S6K1 in regulation of SREBP1c expression in the liver.

Li, S., Ogawa, W., Emi, A., Hayashi, K., Senga, Y., Nomura, K., Hara, K., Yu, D., & Kasuga, M. (2011) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2011.07.038 · Cited by 87 · see citing works

Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy

Zhou, W. P., & Ye, S. (2018) · Cell Biology International · doi:10.1002/cbin.11015 · Cited by 87 · see citing works

mTOR signalling and metabolic regulation of T cell differentiation

Peter, C., Waldmann, H., & Cobbold, S. P. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.08.010 · Cited by 85 · see citing works

Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels

Pinyopornpanish, K., Leerapun, A., Pinyopornpanish, K., & Chattipakorn, N. (2021) · Gut and Liver · doi:10.5009/gnl20367 · Cited by 81 · see citing works

NASH drug treatment development: challenges and lessons

Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81 · see citing works

S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy

Espeillac, C., Mitchell, C., Celton‐Morizur, S., Chauvin, C., Koka, V., Gillet, C., Albrecht, J. H., Desdouets, C., & Pende, M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44203 · Cited by 80 · see citing works

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis

Dagorn, P. G., Foretz, M., Steinberg, G. R., Batchuluun, B., Zawistowska‐Deniziak, A., Lambooij, J. M., Guigas, B., Carling, D., Monternier, P., Moller, D. E., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1799 · Cited by 78 · see citing works

Liver-specific p70 S6 Kinase Depletion Protects against Hepatic Steatosis and Systemic Insulin Resistance*

Bae, E., Xu, J., Oh, D., Bandyopadhyay, G., Lagakos, W., Keshwani, M. M., & Olefsky, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365544 · Cited by 75 · see citing works

Weighing In on mTOR Complex 2 Signaling: The Expanding Role in Cell Metabolism

Luo, Y., Xu, W., Li, G., & Cui, W. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7838647 · Cited by 74 · see citing works

mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease

Feng, J., Qiu, S., Zhou, S., Tan, Y., Bai, Y., Cao, H., Guo, J., & Su, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169196 · Cited by 74 · see citing works

Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review

Riazi, K., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A. A. (2022) · Nutrients · doi:10.3390/nu14214556 · Cited by 71 · see citing works

Insulin Regulates Hepatic Triglyceride Secretion and Lipid Content via Signaling in the Brain

Scherer, T., Lindtner, C., O’Hare, J., Hackl, M. T., Zieliński, E., Freudenthaler, A., Baumgartner-Parzer, S. M., Tödter, K., Heeren, J., Krššák, M., et al. (2016) · Diabetes · doi:10.2337/db15-1552 · Cited by 68 · see citing works

Epidemiology of non‐alcoholic fatty liver disease‐related hepatocellular carcinoma and its implications

Wong, S., Ting, Y., & Chan, W. (2018) · JGH Open · doi:10.1002/jgh3.12070 · Cited by 68 · see citing works

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kim, K., & Lee, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0137 · Cited by 68 · see citing works

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy

Bouyahya, A., Allam, A. E., Aboulaghras, S., Bakrim, S., Menyiy, N. E., Alshahrani, M. M., Awadh, A. A. A., Benali, T., Lee, L., Omari, N. E., et al. (2022) · Cancers · doi:10.3390/cancers14225520 · Cited by 66 · see citing works

Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets

Chen, Y.-S., Wang, W., Morgan, M., Robson, T., & Annett, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148934 · Cited by 63 · see citing works

TFEB is a central regulator of the aging process and age-related diseases

Abokyi, S., Ghartey‐Kwansah, G., & Tse, D. Y. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101985 · Cited by 59 · see citing works

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

Fouqueray, P., Bolze, S., Dubourg, J., Hallakou‐Bozec, S., Theurey, P., Grouin, J., Chevalier, C., Dagorn, P. G., Moller, D. E., & Cusi, K. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100474 · Cited by 52 · see citing works

Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis

Uehara, K., Sostre‐Colón, J., Gavin, M. J., Santoleri, D., Leonard, K., Jacobs, R. L., & Titchenell, P. M. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.015 · Cited by 51 · see citing works

Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Chen, B. W., Chen, W., Liang, H., Liu, H., Liang, C., Zhi, X., Hu, L.-Q., Yu, X.-Z., Wei, T., Ma, T., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0029 · Cited by 50 · see citing works

Insulin Regulation of Hepatic Lipid Homeostasis

Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49 · see citing works

Depletion of Gut Microbiota Inhibits Hepatic Lipid Accumulation in High-Fat Diet-Fed Mice

Han, H. L., Wang, M., Zhong, R., Yi, B., Schroyen, M., & Zhang, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169350 · Cited by 49 · see citing works

mTOR is a Key Protein Involved in the Metabolic Effects of Simple Sugars

Sangüesa, G., Roglans, N., Baena, M., Velázquez, A. M., Laguna, J. C., & Alegret, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051117 · Cited by 48 · see citing works

The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database

Alkhouri, N., Almomani, A., Le, P., Payne, J. Y., Asaad, I., Sakkal, C., Vos, M. B., Noureddin, M., & Kumar, P. N. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02430-7 · Cited by 48 · see citing works

Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease

Chen, H. (2020) · Liver Research · doi:10.1016/j.livres.2020.02.004 · Cited by 47 · see citing works

Non-alcoholic fatty liver disease-related hepatocellular carcinoma

Daher, D., Dahan, K. S. E., & Singal, A. G. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2022.12.30 · Cited by 43 · see citing works

Trust is good, control is better: technical considerations in blood microbiome analysis

Schierwagen, R., Silva, M. C. A., Servant, F., Trebicka, J., Lelouvier, B., & Arumugam, M. (2019) · Gut · doi:10.1136/gutjnl-2019-319123 · Cited by 39 · see citing works

Cytoplasmic Endonuclease G promotes nonalcoholic fatty liver disease via mTORC2-AKT-ACLY and endoplasmic reticulum stress

Wang, W., Tan, J., Liu, X., Guo, W., Li, M., Liu, X., Liu, Y., Dai, W., Hu, L., Wang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41757-x · Cited by 37 · see citing works

Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis

Hansen, H. H., Pors, S. E., Andersen, M. W., Vyberg, M., Nøhr-Meldgaard, J., Nielsen, M. H., Oró, D., Madsen, M. R., Lewińska, M., Møllerhøj, M. B., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-50328-5 · Cited by 37 · see citing works

Inhibition of ghrelin o-acyltransferase attenuated lipotoxicity by inducing autophagy via AMPK–mTOR pathway

Zhang, S., Mao, Y., & Fan, X. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s158985 · Cited by 36 · see citing works

Identification of Hepatocellular Carcinoma-associated Hub Genes and Pathways by Integrated Microarray Analysis

Liu, F., Li, H., Chang, H., Wang, J., & Lu, J. (2015) · Tumori Journal · doi:10.5301/tj.5000241 · Cited by 34 · see citing works

Development of hepatocellular cancer induced by long term low fat-high carbohydrate diet in a NAFLD/NASH mouse model

Tessitore, A., Mastroiaco, V., Vetuschi, A., Sferra, R., Pompili, S., Cicciarelli, G., Barnabei, R., Capece, D., Zazzeroni, F., Capalbo, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18585 · Cited by 32 · see citing works

TFEB: A Emerging Regulator in Lipid Homeostasis for Atherosclerosis

Li, M., Wang, Z., Wang, P., Li, H., & Yang, L. M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.639920 · Cited by 32 · see citing works

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients

Paklar, N., Mijić, M., & Filipec-Kanižaj, T. (2023) · Biomedicines · doi:10.3390/biomedicines11113096 · Cited by 31 · see citing works

mTORC1 restrains adipocyte lipolysis to prevent systemic hyperlipidemia

Paolella, L. M., Mukherjee, S., Tran, C. M., Bellaver, B., Hugo, M., Luongo, T. S., Shewale, S. V., Lu, W., Chellappa, K., & Baur, J. A. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.003 · Cited by 30 · see citing works

Up-to-date global epidemiology of nonalcoholic fatty liver disease

Manikat, R., Ahmed, A., & Kim, D. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-548 · Cited by 30 · see citing works

Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma

Márquez-Quiroga, L. V., Arellanes‐Robledo, J., Vásquez-Garzón, V. R., Villa‐Treviño, S., & Muriel, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114845 · Cited by 29 · see citing works

Inflammatory processes involved in NASH-related hepatocellular carcinoma

Cannito, S., Dianzani, U., Parola, M., Albano, E., & Sutti, S. (2023) · Bioscience Reports · doi:10.1042/bsr20221271 · Cited by 28 · see citing works

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies

Chaudhary, S. P., Reyes, S., Chase, M. L., Govindan, A., Zhao, L., Luther, J., Bhan, I., Bethea, E., Franses, J., Walsh, E. P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyac251 · Cited by 24 · see citing works

Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction–Associated Steatotic Liver Disease: Progress But With Challenges

Allen, A. M., Pose, E., Reddy, K. R., Russo, M. W., & Kamath, P. S. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.11.007 · Cited by 22 · see citing works

Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies

Zhao, Y. M., Zhao, W., Ma, J., Toshiyoshi, M., & Zhao, Y. (2023) · Medicine · doi:10.1097/md.0000000000033110 · Cited by 20 · see citing works

Inhibitory effects of rapamycin on the different stages of hepatic fibrosis

Kim, Y. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7452 · Cited by 19 · see citing works

mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans

Okuno, T., Kakehashi, A., Ishii, N., Fujioka, M., Gi, M., & Wanibuchi, H. (2018) · Cancers · doi:10.3390/cancers10120465 · Cited by 19 · see citing works

Progression of liver disease in non‐alcoholic fatty liver disease: A prospective clinicopathological follow‐up study

Chan, W., Hilmi, I. N., Cheah, P., & Goh, K. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12175 · Cited by 17 · see citing works

Role of mechanistic target of rapamycin in autophagy and alcohol-associated liver disease

Chao, X., Williams, S. N., & Ding, W. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00281.2022 · Cited by 17 · see citing works

Rapamycin suppresses inflammation and increases the interaction between p65 and IκBα in rapamycin-induced fatty livers

Ge, C., Ma, C., Cui, J., Dong, X., Sun, L., Li, Y., & Yu, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281888 · Cited by 14 · see citing works

Type 2 diabetes originated from non-alcoholic fatty liver disease

Xiong, X., & Li, X. (2023) · Life Metabolism · doi:10.1093/lifemeta/load007 · Cited by 11 · see citing works

General Overview About the Current Management of Nonalcoholic Fatty Liver Disease

Ampuero, J. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01142-w · Cited by 10 · see citing works

Pharmacological effects of mTORC1/C2 inhibitor in a preclinical model of NASH progression

Arora, M., Pavlíková, Z., Kučera, T., Kozlík, P., Šopin, T., Vacı́k, T., Ľupták, M., Duda, M., Slanař, O., & Canová, N. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115447 · Cited by 9 · see citing works

Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC

Kroh, A., Walter, J., Fragoulis, A., Möckel, D., Lammers, T., Kiessling, F. M., Andruszkow, J., Preisinger, C., Egbert, M., Jiao, L. R., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100945 · Cited by 8 · see citing works

Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma

Green, C. D., & Spiegel, S. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100925 · Cited by 3 · see citing works

The role of Salvia miltiorrhiza compounds in hepatocellular carcinoma: a preliminary investigation based on computational analysis and liquid chromatography-tandem mass spectrometry

Ge, G., Jiang, X., Tian, X., Zhou, Y., & Cao, G. (2025) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2025.04.001 · Cited by 15 · see citing works

Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease

Jin, X., Song, S. J., Lai, J. C., Wong, G. L., Kong, A. P. S., Peng, N., Xiao, X., Wong, V. W., & Yip, T. C. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0860 · Cited by 5 · see citing works

Erk1R84H is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop

Soudah, N., Baskin, A., Darash‐Yahana, M., Darlyuk‐Saadon, I., Smorodinsky-Atias, K., Shalit, T., Yu, W., Savidor, A., Pikarsky, E., & Engelberg, D. (2025) · Oncogene · doi:10.1038/s41388-025-03437-6 · Cited by 4 · see citing works

Targeting the AMP-activated protein kinase pathway: the active metabolites of botanical drugs represent potential strategies for treating metabolic-associated fatty liver disease

Liang, Q., Li, A., He, L., Li, W., & Wang, J.-L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681880 · Cited by 4 · see citing works

Liver steatosis is positively associated with plasminogen activator inhibitor-1 in apparently healthy individuals with overweight and obesity: A FibroScan-Based Cross-Sectional study

Lisco, G., Guido, D., Cerabino, N., Chito, M. D., Donvito, R., Bonfiglio, C., Shahini, E., Zappimbulso, M., Randazzo, C., Barletta, D., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06464-9 · Cited by 4 · see citing works

Pathogenic effects of telomerase reverse transcriptase (TERT) promoter mutations in nonalcoholic steatohepatitis (NASH) related hepatocellular carcinoma (HCC) and its potentials as a diagnostic biomarker

Liman, U. U., Hawage, A. S., Silva, S. D., Samarasinghe, S. M., Tennekoon, K. H., Siriwardana, R. C., & Niriella, M. A. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00738-z · Cited by 3 · see citing works

Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells

Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2 · see citing works

A roadmap to unveil the mechanism(s) of natural indole-derived molecules against NAFLD-derived HCC via systems pharmacology

Oh, K., Kwon, G.-H., Lee, K. J., Eom, J. A., Kim, D. J., & Suk, K. T. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102618 · Cited by 2 · see citing works

Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050

Shi, J., Wu, X., Yu, J., & Zhou, Q. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1651357 · Cited by 1 · see citing works

Mendelian randomization analysis reveals no causal association between non-alcoholic fatty liver disease and hepatocellular carcinoma: implications for lipid metabolomics and shared pathophysiological mechanisms

Wei, Y., & Li, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-03582-0

Liver injury in a preclinical model of short bowel syndrome is associated with impaired autophagy

Alligood, D. M., Park, A. J., Swanson, K. A., Pyarali, N., Mayse, E., Alvarado, D. M., Liu, X., Kim, J.-S., Davidson, N. O., Rubin, D. C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-30243-7

Signaling Pathway Remodeling and Molecular Regulation in the HCC TME: Dynamic Evolution and Clinical Therapeutic Advances

Xu, L., Zhang, X., Zhu, H., Niu, D., Zhu, X., & Jin, C. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl45415

Exploiting Heterogeneous Labels in Deep Learning for Medical Image Analysis : Application to the Automated Diagnosis of Liver Diseases

Sarfati, E. (2025) · theses.fr (ABES) · doi:10.70675/c8de34e7z1fa6z42cbza183z1e37c1b52362

The Diverse Landscape of Cancer Genomics in Africa

Karla, C. S. S., Chiara, L. M. F., Wium, M., Maria, S. Z., Stefano, C., Lara, D., & Zerbini, L. F. (2026) · Nature anthropology · doi:10.70322/natanthropol.2026.10008

Therapeutic targeting of the PRMT6/FOXK1 axis restores lipid homeostasis and ameliorates hepatic steatosis and steatohepatitis in mice

Sun, Y., Chen, T., Zhang, L., Duan, J., Xue, J., Huang, W., Di, J.-Z., & Zhang, Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.003

Metabolic signatures in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma

Fan, W.-J., Wu, Y.-M., Liu, X.-Y., Zhang, C.-A., Hu, C., Wang, B.-B., & Ding, H. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.08.008

IDDF2019-ABS-0221 Metabolic-immunoregulatory role of mTOR signaling in NAFLD-associated hepatocellular carcinoma

Tang, W., Zhou, J., Yang, W., Feng, Y., Mok, M. T., & Cheng, A. S. (2019) · Gut · doi:10.1136/gutjnl-2019-iddfabstracts.100

HCC in Patients with NAFLD/NASH

Stefano, J., Malta, F. D. M., de Campos, P. B., Andrade, P., Paranaguá-Vezzozo, D. C., Carrilho, F., & Oliveira, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-37173-9_11 · Cited by 1 · see citing works

mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis

Arora, M., Canová, N. K., & Farghali, H. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174857 · Cited by 17 · see citing works

NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome

Michelotti, A., de Scordilli, M., Palmero, L., Guardascione, M., Masala, M., Roncato, R., Foltran, L., Ongaro, E., & Puglisi, F. (2021) · Cells · doi:10.3390/cells10082034 · Cited by 37 · see citing works

Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis

Kakehashi, A., Suzuki, S., & Wanibuchi, H. (2023) · Cancers · doi:10.3390/cancers15184566 · Cited by 19 · see citing works